Treatment of migraine attacks based on the interaction with the trigemino-cerebrovascular system.
Primary headaches such as migraine are among the most prevalent neurological disorders, affecting up to one-fifth of the adult population. The scientific work in the last decade has unraveled much of the pathophysiological background of migraine, which is now considered to be a neurovascular disorder. It has been discovered that the trigemino-cerebrovascular system plays a key role in migraine headache pathophysiology by releasing the potent vasodilator calcitonin gene-related peptide (CGRP). This neuropeptide is released in parallel with the pain and its concentration correlates well with the intensity of the headache. The development of drugs of the triptan class has provided relief for the acute attacks but at the cost of, mainly cardiovascular, side effects. Thus, the intention to improve treatment led to the development of small CGRP receptor antagonists such as olcegepant (BIBN4096BS) and MK-0974 that alleviate the acute migraine attack without acute side events. The purpose of this review is to give a short overview of the pathological background of migraine headache and to illustrate the mechanisms behind the actions of triptans and the promising CGRP receptor blockers.
Link
Andrea Stephanie
AS
Biomedical Center Lund, Lund, Sweden.
Kuris
Anikó
A
Edvinsson
Lars
L
D000818:Animals; D001381:Azepines / Q000494:pharmacology / Q000627:therapeutic use; D015740:Calcitonin Gene-Related Peptide / Q000037:antagonists & inhibitors* / Q000378:metabolism; D000077221:Calcitonin Gene-Related Peptide Receptor Antagonists; D002536:Cerebral Arteries / Q000187:drug effects* / Q000294:innervation / Q000503:physiopathology; D004151:Dipeptides / Q000494:pharmacology / Q000627:therapeutic use; D006801:Humans; D007093:Imidazoles / Q000494:pharmacology / Q000627:therapeutic use; D008881:Migraine Disorders / Q000188:drug therapy* / Q000378:metabolism / Q000503:physiopathology; D010879:Piperazines; D011799:Quinazolines / Q000494:pharmacology / Q000627:therapeutic use; D018015:Receptors, Calcitonin Gene-Related Peptide / Q000378:metabolism; D014276:Trigeminal Nerve / Q000187:drug effects* / Q000378:metabolism / Q000503:physiopathology; D014363:Tryptamines / Q000494:pharmacology / Q000627:therapeutic use; D014664:Vasodilation / Q000187:drug effects / Q000502:physiology
D001381:Azepines; D000077221:Calcitonin Gene-Related Peptide Receptor Antagonists; D004151:Dipeptides; D007093:Imidazoles; D010879:Piperazines; D011799:Quinazolines; D018015:Receptors, Calcitonin Gene-Related Peptide; D014363:Tryptamines; C525458:telcagepant; D015740:Calcitonin Gene-Related Peptide; C406305:olcegepant